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ABSTRACT

This case report follows the treatment of a 64 year old male with a Charcot foot
ulceration of the right foot. The study was conducted to assess the outcome of wound care to the
stage three pressure ulcer and the use of a Total Contact Cast (TCC) in the treatment of the
Charcot foot ulceration, as well as to present more awareness to the medical field on Charcot
foot pathology and diagnosis. The study was conducted over a 16 week time period. After 15
sessions with the patient, the results showed that wound care, the use of a TCC, and custom
shoes and orthotics were beneficial in treating and healing the Charcot foot ulceration.
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CHAPTER 1
BACKGROUND AND PURPOSE

Over the last decade, the number of people diagnosed with Charcot neuropathies has
significantly increased. This is probably due to the fact that the occurrence of diabetic
neuropathy has increased. However, the actual incidence of Charcot neuropathy is predicted to
be higher since many cases go undiagnosed. 1 The lack of knowledge on the pathophysiology,
and clear clinical and radiologic diagnostic criteria, has made it difficult to correctly diagnose
cases of Charcot foot. 2
Charcot neuropathy is a progressive and disabling deterioration of weight-bearing joints,

c

in which the ankle and foot are usually affected. The most commonly affected area of the foot is
the tarsometatarsal or Lisfranc joint? The pathophysiology of Charcot neuropathy is not well
comprehended, but it is assumed to be due to multiple factors. First, the loss of protective pain
sensation and proprioception allows for repetitive micro- and macrotrauma producing joint and
periarticular soft tissue damage. Continued weight bearing on the joint and further tissue
damage then leads to gross deformities. Second, the abnormal vasomotor regulation, which
results from autonomic denervation, can contribute to a pathological change. Third,
neuroarthropathic patients have increased lower limb blood flow and arteriovenous shunting.
This is most likely associated with increased osteoclastic activity and bone resorption. Finally,
impairment of the innervations of the intrinsic muscles of the foot may alter the loading
characteristics of the foot. The impaired intrinsic muscles can cause increased heel and plantar
forces which can produce eccentric loading of the foot, generating micro-fractures and ligament
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laxity, which encourages joint instability and bony destruction. Together, these factors have a
role in the Charcot process. 1, 3
People with diabetes who have mild to severe neuropathies are most often affected, with
diabetes being considered to be the most common cause worldwide. I ,2 In 2002, the Charcot foot
was assumed to affect approximately 0.2 percent of the diabetic population. Charcot foot occurs
even more exclusively in those with diabetes who are in their fourth or fifth decade of life, and
who have had diabetes for 10 years or more. 4 This complication, which can develop very
quickly, can lead to disruption of the bony foot architecture, deformed "rocker-bottom" foot,
recurrent foot ulceration, and eventually, amputation. I, 2 Out of all individuals with diabetes,
approximately 15% of them will develop a foot ulcer within their lifetime, and 84% of the time
the ulcers precede a lower extremity amputation. 5 As a result, patients with diabetes account for
approximately one-half of non-traumatic lower extremity amputations in the u.s. every year. 6
Clinical diagnosis of the Charcot foot is difficult to make and often leads to a
misdiagnosis such .as gout, osteoarthrosis/arthritis, fracture, or cellulitis. The average delay from
initial symptoms to making the correct diagnosis is around 29 weeks. This is partially due to
physician misdiagnoses given that the condition is not widely recognized outside of specialist
clinics, and that the clinical diagnosis during the acute stage of Charcot neuropathy is not easy to
make. Another key factor in the delay of a correct diagnosis is the patients underrating the
symptoms of a swollen and red, but often painless foot. Therefore, more often than not, the
acute phase goes completely urmoticed.\' 2 The clinical presentation of Charcot neuropathy is
commonly seen as erythema, edema, and an increased temperature of the foot compared to the
contralateral side, along with normal appearing radiographs. 2,3 Radiologic measures often have a
hard time distinguishing acute Charcot foot from other diseases as well. X-ray radiography often
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is unable to show any signs of a fracture or dislocation. Only magnetic resonance imaging
(MRI) has been able to reveal, in detail, the inflammation within the bone, the nature of the
boney damage, and the condition of the surrounding soft tissue. The MRI is especially useful in
the acute stage of the Charcot foot. I, 2 A variety of laboratory tests are also typically performed,
including an erythrocyte sedimentation rate and white blood cell count. However, they tend to
have low sensitivity and do not help distinguish if there is infection along with the Charcot
changes. 3
Due to devastating results of Charcot neuropathies, and the increase in
prevalence, it is becoming even more important for clinicians and other health care workers to be
aware of this diagnosis. Early recognition and intervention for this syndrome can help minimize
deformity and ultimately amputation. Another imperative reason for physicians and health care
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workers to be aware of this diagnosis is that the mortality in patients presenting with either an
acute Charcot foot and/or an uninfected neuropathic ulcer is unexpectedly high. In a study7 done
in the United Kingdom (U.K.), the median survival for patients, with a mean age of 58 years,
presenting with an acute Charcot foot to a single u.K. center between 2000 and 2007 was
reduced from approximately 22 to 8 years. The poor survival of patients with an acute Charcot
foot may be largely attributable to the distal symmetrical neuropathy with which the Charcot
condition is universally associated. 7 Physicians should always consider the possibility of
Charcot foot when examining a patient who is diabetic and presents with a swollen foot. Charcot
process should especially be considered with the absence of fever, elevated C-reactive protein or
erythrocyte sedimentation rate, which indicates that an infection is highly unlikely. 1 The goal of
intervention should be to stop the inflammation and disrupt the destruction process that is
occurring in the foot, as well as to maintain adequate alignment and architecture of the foot and
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ankle in order to prevent deformity. I, 2 Currently, total non-weight bearing is considered crucial
to the successful treatment of the Charcot foot in the initial stages. 1,3 Even brief periods of
weight bearing can delay or prevent healing. 6 Total non-weight bearing is commonly achieved
with below the knee total contact casts (TCC); this is considered to be the gold standard
intervention. 1, 3 When the acute stage has diminished, assisted or partial weight bearing can be
gradually introduced. During this portion of the intervention, not only does the amount of
weight need to be limited but also the patients amount of participation in exercise. Other
interventions include: pressure relieving devises such at shoes, orthotics, removable total contact
cast (RCC), prefabricated pneumatic walking brace (PPWB), and shoe-model casts. 3, 8,9 Surgical
intervention may be required for patients with marked instability, severe deformity and recurrent
ulcerations. Currently, the most common operative procedure is the removal of the osseous

(

prominence of the Charcot foot that is located on the medial or plantar aspect of the foot. I
Intervention should also focus on prevention of Charcot deformity of the patient's contralateral
foot, since about 25 percent of patients ultimately do develop similar changes on their
contralateral foot within a couple years. 3, 4
The purpose of this case study is to educate people on the pathology, diagnosis
and possible interventions of the Charcot foot in an attempt to reduce the prevalence of
undiagnosed and misdiagnosed cases.

L
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Chapter 2
CASE DESCRIPTION

The patient is a 64 year old white male. He is a retired Vietnam Veteran. The patient
lives with his wife. Patient's past medical history and current problems are listed in Table 1 and
includes:

Table 1: Patient's past medical history and current problems

(

Hypertension Nos (nitric oxide synthase)

Diabetic Neuropathies

Hyperlipidemia, mixed

Diabetic Foot Ulcer

Arthropathy, Neurogenic

Diabetes Mellitus Type II

Renal Failure

Pes Planus

Height and weight measurements of the patient are 72in and 214.61bs respectively. He
has a BMI of29.17, which is considered overweight. The patient is allergic to Penicillin.

I
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Currently the patient's active medications include:
Table 2: Patient's active medication list

c

Medication

Indication

Amlodipine Besylate - Smg tablet

Treatment of hypertension

Cholecalciferol (vitamin 3D) - 1000 unit tablet

VitaminD3

Simvastatin - 80mg tablet

Help control cholesterol

Lisinopril - 40mg tablet

Treatment of high blood pressure

Insulin, Aspart, Human 100 UnitIMI Inj

Treatment of diabetes

Insulin, Glargine, Human 100 UnitIMI Inj

Treatment of diabetes

The patient was referred to Physical Therapy (PT) by a M.D. for a diagnosis of a diabetic
foot wound. The PT diagnosis, stage 3 pressure ulcer to the right foot at the Charcot joint, did
support that of the M.D diagnosis of a diabetic foot wound. A pressure ulcer is stated to be "a
localized injury to the skin and lor underlying tissue, usually over a bony prominence, as a result
of pressure, or pressure in combination with shear and/or friction."lo More specifically, stage 3
pressure ulcers are defmed as: full-thickness skin loss involving damage or necrosis of
subcutaneous tissue that may extend down to, but not through, underlying fascia; the ulcer
presents clinically as a deep crater with or without undermining of adjacent tissue. I I

6

The wound was assessed for infection, size, drainage, and odor. Wound base was 90%
pink and 10% yellow. There were signs of infection including: increased drainage, edema, and
inflammation. Drainage from the wound was Serosanguinous and purulent, therefore containing
serum, blood and pUS. 12 The wounds periwound, skin surrounding the wounds perimeter,

12

was

intact. The wound size was measured with a Dermagraft one-time use ruler. The wound
measurements were determined to be 17 mm height x 15 mm width x 5 mm depth. The wound
also had a tunnel that measured 12 mm in length. A picture was taken of the wound for
documentation purposes and the wound was also sharp debrided with a scalpel and forceps.
Due to the wound having signs of infection, and the patient presented with acute
inflammation of the foot, redness and increased temperature compared to the contralateral foot, a
culture of the wound was taken. The patient did not have a TCC applied at the initial evaluation
(

as a precaution in case of a possible infection.
An MRI was also ordered by the M.D. for the right foot to rule out the possibility of
osteomyelitis due to the depth of the wound. Findings of the MRI demonstrated collapse of the
midfoot and deformity and fragmentation of the cuneiforms, navicular, and anterior process of
the talus. The cuboid bone of the foot was also found to be markedly deformed. A small amount
of fluid was also noted to be collecting superficially to the plantar fascia. Bone marrow changes
were noted throughout the adjacent bones; therefore, it was not possible to definitely exclude the
possibility of osteomyelitis based on this patients MR!.
The patient had been to PT previously for the same diagnosis. The patient had Charcot
foot deformity bilaterally. He had two previous ulcers on his right foot at the Charcot joint; the

(

first ulcer was treated 4 years ago, the second ulcer was treated 3 years ago. Previous treatments
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for this diagnosis included: Total Contact Cast (TCC), wound care, custom shoes and orthotics,

'

and slow progression to full weight bearing after the wound healed. The patient had been
wearing custom shoes since 200 1 due to his left foot being diagnosed with Charcot foot. The
patient was also educated on nutrition and given information about diabetes and a nutritional diet
to take home with him.
Goals for PT were to reduce abnormal pressure on the right foot at the Charcot joint and
to resolve the wound. Patient's treatment focused on wound care and pressure reduction with a
TCC, and long term focus on prevention of another ulcer.
A TCC was chosen as the intervention for treating this patient's ulcer due to a number of
different study results. Once the wound was healed, protective foot gear and custom orthotics
would need to be re-evaluated and adjusted if necessary.

(
The patient was a candidate for care and the selected interventions by PT based off of
clinical decision making guidelines. First, since the patient was a veteran, he was eligible for
care at the clinical site. Second, the patient needed care for his wound, and PT was
knowledgeable and had proper resources and equipment available to treat the patients wound.

I
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Chapter 3

\

INTERVENTION

The main interventions for the patient in this case included: wound care treatment and
immobilization with the use of a TCC to prevent bearing weight on the affected limb. Wound
care treatment consisted of sharp debridement of the wound area with a scalpel and forceps. The
wound was flrst cleaned with a 4x4 piece of gauze sprayed with CarraKlenz wound cleaner.
Skin-Prep was then applied around the edges of the wound as a protective mm to help prepare
the skin for the attachment of the adhesive dressings to be used and prevent maceration.
Collagen flakes and Silver Powder Arglaes were then applied to the wound bed to help further
r-

(-

the wound healing and to help manage exudates and infection respectively. Then, Mepilex Ag,
an antimicrobial soft silicone foam dressing, was placed over the wound bed and held in place
with Mediflx tape. After the wound care was completed; the TCC was applied.
The TCC should be applied with the goals of exact conformity to the lower extremity and
to create evenly distributed pressure across the plantar surface of the foot. The application of the
TCC is as follows: the patient has a tubular post-op stocking placed over their leg, and then lowdensity foam applied over the malleoli, tibial crest, and metatarsal heads. A plastic shell and
outer flberglass shell make up the cast. The cast needs to be changed every week, to allow for
wound care treatment to be performed. 3
Due to the patient having previous Charcot foot ulcerations, patient education on the
Charcot foot disease was not needed. The patient was re-educated however on limiting his

9

amount of activity. Once the patient was no longer required to wear the TCC, he was reeducated on partial weight bearing and crutch walking.
Interventions by date for the patient are listed in table 3 on the next page and were as
follows:

c
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Table 3: Interventions per physical therapy session
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The patient was scheduled to be seen via Telehealth the next week at his hometown clinic
for an update on his wound area. Unfortunately, the patient had to be seen again in the clinic due
to skin break down. The wound measured to be .5cm round with .2cm depth. The patient was
re-casted with a TCC. The patient's wound had full epithelialization after the first week of
wearing the cast, however a decision was made to keep the cast on for a month to make sure that
the skin had an adequate amount of time to heal properly and to decrease the chance of future
skin breakdowns. Interventions by date for the patient when he returned to physical therapy are
listed in table 4 and were as followed:
Table 4: Interventions per physical therapy session

12th

Session

13 Session

th

14th Session

15th Session

Active Wound
Care 20cm or <:
sharp
debridement

:lI

:lI

tj

:lI

Wound
Measurement

:V2 cm round, .2cm
depth

Thin epithelial
layer over wound
site

Full
epithelialization
over wound site

Full
epithelialization
over wound site

TCC Application
Discharge

::!l

::!l

£I

:LI

The patient's skin had not broken down since the last treatment session, which was over 5
months ago.
Debridement is vital in healing diabetic ulcers. It includes removing all surrounding
calluses, necrotic and infected tissue. Debridement is important for healing because it causes
activation of platelets and growth factors that initiate the healing process. The use of topical
silver applications, such as the Silver Powder Arglaes which was used with this patient, are
(,
(
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commonly used due to the silver cation which has been shown to effectively kill antibiotic12

(\

resistant strains of bacteria. Tissue should be kept moist after debridement to prevent deepening
of the wound and facilitate cell growth. Dressings should be determined based upon the patients
wound location, depth, amount of slough or exudates present, the presence of infection,
condition of the wound margins, need for adhesiveness, and conformability ofthe dressing being
used. 12
Studies2 , 3, 8,9, 12, 13 have stated that immobilization, to prevent weight bearing and to
create effective off-loading ofthe affected limb, is a key element in treating diabetic foot ulcers,
and have identified the Tee as the gold standard of treatment. Due to the minimal padding and
careful conformity of the cast to the shape of the affected foot, Tee redistributes the weight
away from the ulcer site, while still allowing patients to walk. 6, 13 Tees have been shown to
reduce pressure over the plantar aspect of the foot, at the site of the ulceration, by 84_92%.13

C

Since Tee needs careful conformity to the affected foot, application of a Tee does require
specially trained personnel. If the Tee is applied inappropriately, there is a risk of the ulcer
worsening. 12 When compared to conventional dressings, Tees were found to be effective in
treating ulcers and were associated with an increased number of ulcers healing. 8 One study9
concluded that the Tee heals ulcers in a relatively short amount of time, median of 33 days, and
has healing rates of approximately 76%. Patients in that study remained in the Tee until they
had intact skin over the wound area. Once healing was complete, the challenge was to keep the
fragile new tissue overlying the healed ulcer from breaking open again' since the new tissue was
very vulnerable in the period immediately after casting. As a result, one article recommended
that a Tee be used for two additional weeks after healing. 6 Another studyS recommended that
the Tee be worn for a minimum of 8-12 weeks, followed by gradual assisted weight bearing and

L,

limited exercise. Once the wound was healed, protective foot gear and custom orthotics need to
13
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be ordered for the patient if they do not own some already, or possibly altered if the patient
already uses custom orthotics.
TCCs are also beneficial and effective for control of lower extremity edema. This can
contribute to improved conditions for wound healing in the presence of a pressure ulcer, as well
as immobilization of the joints of the foot and ankle helps to relieve mechanical shear stress in
the tissues. A TCC may be contraindicated in patients with a history of thromboembolism or a
significant infection. 6
Intervention of a TIC was selected for this patient due to study results and the patient's
previous two outcomes with the use of this intervention for the same diagnosis.
Coordination with a local prosthetist was needed for the alteration of the patient's custom

c

orthotics and shoes. During the time the patient was being treated, the prosthetist resoled both of
the patient's custom shoes and adjusted his custom orthotics to fit the Charcot foot deformities.
The prosthetist also lined the patient's orthotics with a silicone liner. Since it is common in
neuropathic limbs for an ulceration to present in the contralateral limb within 36 months after the
first limb presents with an ulcer,14 care was taken to make sure both of the patient's shoes and
orthotics fit properly to the patient's feet and Charcot deformity.
After the patient's wound healed, the patient was re-educated on crutch walking with
50% weight bearing. A scale was used to help show the patient what 50% weight-bearing felt
like. He was also instructed on how to progress to full weight bearing in one month.
Wound care, the use of a TCC, and alterations to custom shoes and orthotics proved to be
useful interventions for the treatment ofthis patient's Charcot foot ulceration.

L
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CHAPTER 4
OUTCOMES

The patient's Charcot foot ulcer, of the right foot, has continued to remain healed since
he was discharged. Data collected from measurements taken over the course of this case study
include: range of motion (ROM), wound size and assessments, ligament testing, effusion, and
risk for future ulcers. All results from the measurement are listed below in table 5 and table 6:

Table 5: Measurement Data of ROM, Sensation, and Special Test Re-evaluation

c
Hip Flexion
Hip Internal Rotation
Hip External Rotation
Left Knee Flexion
Right Knee Flexion
Knee Extension
Dorsiflexion of right foot
with knee straight
Dorsiflexion of right foot
with knee bent
Lachman's Test
VarusNalgus
Sensation

9th Session
110° Bilaterally
20° Bilaterally
40 0 Bilaterally
120°
130°
0° Bilaterally

11 th Session

2°
10°
(+) on Left knee
WNL Bilaterally
Lack of sensation distal to the
calf bilaterally

WNL - within normal limits

L
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(1st Session
Height

Width
Depth
Tunne
I
Signs
of
infection

Wound
Base

Drainage

Braden
Scale
Score

1.7cm

1.6cm
.Scm
1.2cm
Yes;
increased
drainage,
edema,
and
inflammation
90% PInk,
10%
Yellow
Serosanguinous
and
Purulent
24

~)

(\

2no
Session
2.3cm

1.8cm
.Scm
1.2cm

90%
Pink,
10%
Yellow
Serous

3m
Session
2.3cm

I.Scm

Serous

4Ul
Session
2cm

1.7cm

80%
Pink,
20%
Yellow
Minima
I Serous

511

611

711

gin

91n

Session
1.9cm

Session
I.Scm

Session
1.0cm

Session
.9cm

Session
.3-.4cm

1.8cm

.3-.4em
.1cm

1.2cm
.2em

1.0cm
.1-.2cm

1.0cm

100%
Pink

100%
PInk

100%
Pink

100%
Pink

100%
Pink

Minima
I Serous

Minima
I Serous

Minima
I Serous

Minima
I Serous

Minima
I Serous

24

Table 6: Wound Assessment Measurement Data
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Session
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closed
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Session
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n.No
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tissue to
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12m
Session
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round
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13 111

Session
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site

I
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The Braden Scale was assessed on the patient at the first session to predict the patient's pressure
ulcer risk. Due to prevention and management of pressure ulcers consuming a large amount of
resources in health care settings, preventative programs for at risk patients have been
implemented and have shown to be effective in reducing prevalence rates. The Braden Scale is
one measure used to identify patients who are at risk, which is a vital first step in pressure ulcer
prevention. There are several scales for determining pressure ulcer risk, some including the
Norton Scale, the Waterlow Scale, etc, but the Braden Scale is the most frequently used scale in
the United States for evaluating the degree of risk for pressure ulcer development. 10
The Braden Scale is a norm-reference scale, more than 11 published studies have
provided supporting statistics regarding the Braden Scale as a reliable instrument of pressure
ulcer risk by health professionals, and one systematic review concluded it was the best pressure

C-

ulcer risk assessment. Existing evidence has demonstrated that the Braden Score is both valid .
and reliable with the sensitivity ranging from 61 %-1 00% and specificity ranging from 26%100%. The highest score attainable on the Braden Scale is 23, which indicates the lowest risk for
pressure ulcer development; the lowest possible score is 6, indicating the highest risk. Based on
existing research, the cut-off point varies between a score of 15-18, based on the setting, for
which patients are at a significant risk for pressure ulcer formation. 10
Our patient scored a 23 on the Braden Scale, putting him at the highest risk for pressure
ulcer development, which was logical due to his present wound at the time and having previous
pressure ulcers.
The patient's effusion was not measured specifically, but rather just observed. The
patient's wound was measured by the same PT each session, using a Dermagraft one-time use

17
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ruler. Research l5 has reported the ruler method, which has been found to be reliable, is by far the
most frequently used method to measure wounds because of its inexpensiveness and quickness.
Measuring the wound to the greatest length and greatest width, with the width perpendicular to
the length, has been found to be more valid and reliable than other ruler-based measuring
methods. Digital pictures were also taken with every measurement. This noncontact method has
very good interrater and intrarater reliability and eliminates the chance of wound discomfort. 15
The patient's ROM was measured by the same person consistently and was measured with a
goniometer.
Results of specific testing and evaluations done during the re-evaluation at the 9th session
are as follows: Patient has mild Valgus at the knees, and Charcot deformity of the feet bilaterally.
Charcot deformity is greater on the left midfoot. Pressure areas on the right foot at the mid-
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foot/Charcot area, 2nd metatarsophalangeal (MTP), and navicular area. Pressure areas on the left
foot were at the mid-foot/Charcot area and navicular area. Lachman's test was (+) on left knee.
VarusNalgus was within normal limits bilaterally.
The patient's wound healed and had full epithelialization for two weeks by the 11 th
session. However, the patient's skin broke down again after one week of not wearing a TCC.
The patient was re-casted and after one week of wearing a TCC, the patient's wound had healed
over. The patient was kept in a TCC for 3 weeks to allow the skin over the wound site to have
more time for complete healing. The patient's wound continued to stay healed since when he
was last seen, which has been over 5 months.
Even thought the patient's ulcer has continued to remain healed, the presence of,
specifically, diabetic foot ulcers has been shown to have profound effects on health-related
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quality of life in those patients. It has been thought that foot ulcerations can lead to considerable
negative effects on emotional, physical, and economic functioning for diabetic patients, and can
lead to depression and less satisfaction with life 16 . Our patient specifically will have to tolerate a
few disablements even though his wound has healed, some of which have an impact on his gait,
and his social and emotional levels. The patient has an altered gait due to the altered Charcot
foot formation he presents with bilaterally as well as the custom shoes that he wears. The
patient's activity level, and therefore the amount of walking he can do, is limited. This limitation
also affects the patient socially. He is unable to be out in the community on his feet for a long
period of time, restricting his amount of time to spend with people outside his home. Also, the
custom shoes that are made for patients who need them are very easily recognizable and
although the patient did not state anything during the PT sessions, the appearance of the patients

(

shoes could impact him both socially and emotionally due to the fact that many people would be
able to recognize the difference in his shoes when he is out in the community and may stare or
ask questions related to his shoes or condition. This would have an impact on his emotions, as
well as the constant concern of his feet and whether another ulcer will form. The constant stress
and consistency the patient needs to check his feet for ulcers, as well as the negativity of activity
restrictions and the amount of activity he is able to do, may alter his mood.
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DISCUSSION

After 15 sessions with Physical Therapy, the patient's right Charcot foot ulceration was
healed with the use of wound care and a TCe. The total amount of time needed for healing,
which was defined as intact skin, was 109 days or 15.5 weeks.
One studyl states total non-weight bearing, with a cast, needs to be applied for at least 812 weeks before assisted weightbearing can be gradually started.
Another studyl7 states that the duration ofTCC application is independent of the

(

anatomical site which is involved and progression to protected weightbearing should be based on
clinical judgment. The study also states, that patients with bilateral involvement of Charcot
neuropathy require longer duration of TCC treatment.
In a study9 that assessed the outcome of TCC treatment for foot ulcers in neuropathic
patients with and without peripheral artery disease, the median duration of cast treatment was
found to be 33 days; however, this study also stated that the anatomical location was also clearly
related to the outcome. In this study, 76% of the patients were healed using TCC.
Table 6 from a randomized controlled trial!3, lists a number of offloading modalities and
the mean healing time in days for that intervention. TCC mean healing time was between 28-63
days depending on the anatomical location of the ulcer.
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Table 7- Healing times in common offloading modalities
Offloading modality

Mean healing time (days)

Type of study

Tee

Forefoot ulcers: 30; rearfoot-midfoot
ulcers: 63
Forefoot ulcers: 31; rearfoot-midfoot
ulcers: 42

Retrospective
cohort:
Retrospective
cohort:
Retrospective
cohort:
Retrospective
cohort:
Retrospective
cohort:
Retrospective
cohort:

Tee

l

Tee

40

Tee

38

Tee

44

Tee

Midfoot ulcers: 28

Tee
RCW
Half-shoe

34
50
61

ReT1

42
Tee
Shoe-insole
65
Removable cast boot 48

Fiberglass cast shoe
Fiberglass cast
Shoe
Scotch cast boot

%
healed

Type of wound Ref.

90

Wagner 1,2

Wagner 1,2,34
94

Wagner 1,2

73

Wagner 1,2,33

82

Wagner 1,2

6

100

Wagner 1,2

23

90
65
58

UTIA

9

Wagner 1,2

7

UTIA

16
19

90
32
35
RCT1
Retrospective cohort 91
50
RCTl
21
Retrospective
80

ReT1

34

112, 181

18

Wagner 1
Wagner 1

24

20

Wagner 1, 2,3 25

cohort~

Prospective cohort~ 81

Windowed fiberglass 69
cast
134
Half-shoe
Half-shoe
70
Custom splint

Prospective cohort~

300

70
96

Retrospective

UT2A

21

21
UTIA
Wagner 1,2,3,27
4
22

cohort~

Felted foam dressing 75
85

RCT§.

Wagner 1,2

26

Prospective cohort1 92
93
81
83

Wagner 1,2,328

Half-shoe

Tee
Padded dressing
Healing shoe
Walking splint

48
36
42

51

* Percentage healed in no specified time; tpercentage healed in 12 weeks; t percentage healed in 30 days; §
percentage healed in 10 weeks. RCT, randomized clinical trial. UT, University of Texas.
(
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Our patient had an ulcer that was located in the midfoot region, so according to Table 2,
the median amount of time midfoot ulcers should heal is 28-63 days, which our patient greatly
exceeded. The patient's co-morbidities, including his diagnosis of Charcot foot bilaterally,
severity of his diabetes, and severity of his neuropathy, could have been a causation of his
increased healing time. Other intrinsic factors of this patient, which could have also affected his
tissue tolerance and the length of time it would need for healing, included his nutrition, age, and
arteriolar pressure. 10
More research is needed on finding more effective and time efficient treatments to heal
Charcot foot ulcerations. More research is especially needed in comparing non-weightbearing
methods as well as new interventions that are beginning to be studied as additional methods of
providing non-weightbearing treatment, such as "instant TCC".18
There are many other interventions that are used to help treat plantar ulcers; however they
were not used with this patient. Some of the excluded interventions include: Negative Pressure
Wound Therapy (NPWT), reconstructive therapies, prefabricated pneumatic walking brace
(PPWB), electrical bone stimulation, surgical treatment, and removable cast walkers (RCW). 3, 12,
13, 19

A newer method, off-loading with a removable cast walker, has also been used to treat

plantar ulcers. 18
NPWT was not used with this patient, due to the fact that it is commonly used to manage
extensive and very complex wounds, which the patient in this case study did not present with,
and therefore should be considered in postoperative wounds of the diabetic foot, large foot
ulcers, amputation wounds, or when adequate healing is not occurring after 3-weeks. 12, 19 When
compared to standard treatment for these more complex wounds, NPWT has shown to facilitate
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more rapid healing.

12

NPWT uses a vacuum-assisted closure device and has many benefits

including: providing a closed, moist, wound-healing environment; facilitating wound closure by
drawing the wound edges inward; reducing infection rates; reducing edema; and increasing blood
flow, mitosis, and granulation. 12, 19 Therapy with the use ofNPWT is expensive, but, with the
reduced healing time, it could ultimately provide savings due to decrease dressing costs and staff
time. No major disadvantages have been found with the use ofNPWT other than: pain,
bleeding, patients having to be attached to the machine, and the cost. Caution should be used on
patients with anticoagulation problems. 19
Reconstructive therapies include plastic surgery. This is commonly not used unless the
area of the ulcer has not decreased by more than 10% after other approaches (off-loading with
TCC or NPWT) have been applied for two months. 12

(

A PPWB, is an alternative to TCC. Plantar pressure in the midfoot and forefoot areas is
decreased with the use of a PPWB. Easier surveillance of the ulcer, ease of application, and the
ability to use several different types of dressings are some benefits for PPWB use. However, the
use of a PPWB is not recommended for patients with severe foot deformity or who may be
noncompliant and remove the brace while at home. 3
Electrical bone stimulation can be used to enhance healing. Initial studies show promise
of its use, however, the U.S. Food and Drug Administration has not labeled electrical bone
stimulation as a treatment for Charcot foot. More studies are needed on this treatment. 3
Surgical treatment may be indicated for approximately 25% to 50% of patients with
Charcot arthropathy. For patients where surgery is indicated, the goals of surgery should be to
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restore stability and aligrrrnent, prevent deformity, and to facilitate functional ambulation.
23

Surgery could be indicated with an acute dislocation, recurrent ulcerations, and severe or

f'""
\

I

uncontrolled deformity or instability. 17 Surgery for patients with a stable chronic Charcot foot
or for those patients who experience recurrent or non-healing ulcers would therefore require an
exostosectomy? An exostosectomy (ostectomy) is a procedure done to excise any bony
prominence that could cause an ulcer. For patients with increased plantar pressure, the
completion of this surgery may result in nonappearance of subsequent ulcers in 92% of the
cases. 17 If patients have a markedly unstable extremity, due to a subluxation, a joint
stabilization procedure may be required. 3
Removable cast walkers (RCWs) have been shown in some studies to provide off-loading
which is equal to that of TCCs, but have failed to provide equivalent healing in clinical studies.
In a randomized trial comparing RCWs and TCCs, 65% of ulcers healed in the RCW group
(

compared to 90% of ulcers healed in the TCC group. One benefit of RCW is that clinicians and
therapists, who would not be comfortable applying a TCC due to lack of knowledge or
experience, can readily use a RCW.13
To try and make RCWs more effective, one study, 18 which was the first randomized
clinically controlled trial of this type, created an irremovable TCC (iTCC) and compared the
iTCC to a standard TCe. The iTCC is a RCW rendered irremovable by wrapping a single layer
of fiberglass casting material around it. In this study, mean healing times for the TCC was 5
weeks and 3 weeks for the iTCC. The study suggested that iTCC may be as effective as the
standard TCC in healing and may also have no more or fewer complications, as well as taking
less time to apply and remove. The iTCC was also associated with a lower cost in this study.
More research is needed on the iTCC however due to the study being the first of its kind and a
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relatively small sample size.
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Limitations in this case study would include the fact that as the writer of this case
study, I was not able to continue seeing this patient through the termination of his care, and that
the information had to be sent to me. Also, since the patient lived over 4 hours away from where
we were treating him, his access to health care was limited and we were unable to monitor him
on his amount of activity and weight on his foot after the Tee was removed.
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REFLECTION

I picked this case, on a Charcot foot neuropathy, because of my interest in this disabling
disease. I developed my spark of interest for this topic while on my second clinical rotation
where I was introduced to Charcot foot neuropathies by my CI who worked with a number of
patients who were dealing with different stages and implications from the disorder. Due to the
number of people with diabetes, who are at risk for developing a Charcot foot, the severe
complications and life restrictions that can result, the lack of research and knowledge on the
pathology, and a lack of a proper protocol for treatment, I wanted to do some of my own research
on the topic.

c

From completing this project, I have gained much more knowledge on the pathology of
the disease. I have also learned that currently, treatment and interventions are based on each
patient and can vary greatly. However, one factor that should remain the same in every case is
the careful monitoring of the wound and patience to allow full healing time. I also learned that
there is a great need for more research to be done on this disease, in both diagnosing and treating.
This project has been very beneficial to me, and has helped me learn a lot about a unique
topic that I would not have learned about in school. It also gave me an opportunity to educate
some of my professors and classmates on the topic and make them more aware of the disease.
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Appendix A
Figure 1: Wound Measurement Picture
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Appendix B
Figure 2: Wound Measurement Picture
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Appendix C
Figure 3: Wound Measurement Picture
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Figure 4: Wound Measurement Picture
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Appendix E
Figure 5: Wound Measurement Picture
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Appendix F
Figure 6: Wound Measurement Picture
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Appendix G
Figure 7: Wound Measurement Picture
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Appendix H
Figure 8: Wound Measurement Picture
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Appendix I
Figure 9: Wound Measurement Picture
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Appendix J
Figure 10: Patient Range of Motion Re-evaluation of Ankle Dorsiflexion
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Appendix K
Figure 11: Patient Range of Motion Re-evaluation of Ankle Plantarflexion
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Appendix L
Figure 12: Wound Measurement Picture
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AppendixM
Figure 13: Wound Measurement Picture
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